Trade Date |
Insider |
Title |
Buy or Sell |
Quantity |
Security Type |
Price |
Proceeds |
Transaction Conviction |
Position Quantity |
Position Value |
Positon Conviction |
SEC Link |
Nature of Ownership |
2020-07-01 | Gerrit Klaerner | President and CEO | Sell | 4,000 | Common Stock | $27.15 | $108,600.00 | - | 547,321 | $14,859,765.15 | - | Form 4 | - | 2020-04-06 | Gerrit Klaerner | President and CEO | Sell | 4,000 | Common Stock | $24.22 | $96,880.00 | 0.80 [ High ] | 559,321 | $13,546,754.62 | 111.97 [Very High] | Form 4 | - | 2020-04-15 | Gerrit Klaerner | President and CEO | Sell | 3,900 | Common Stock | $27.46 | $107,094.00 | 0.78 [ High ] | 37,423 | $1,027,635.58 | 7.49 [Average] | Form 4 | By Spouse | 2020-04-15 | Gerrit Klaerner | President and CEO | Sell | 100 | Common Stock | $27.97 | $2,797.00 | 0.02 [ Very Low ] | 37,323 | $1,043,924.31 | 7.47 [Average] | Form 4 | By Spouse | 2020-04-28 | Dawn Parsell Otto | EVP, Clinical Development | Buy | 1,250 | Common Stock | $1.68 | -$2,100.00 | 0.25 [ Low ] | 1,505 | $2,528.40 | 0.30 [Very Low] | Form 4 | - | 2020-04-28 | Dawn Parsell Otto | EVP, Clinical Development | Sell | 1,250 | Common Stock | $29.98 | $37,475.00 | 0.25 [ Low ] | 255 | $7,644.90 | 0.05 [Very Low] | Form 4 | - | 2020-04-29 | Dawn Parsell Otto | EVP, Clinical Development | Buy | 210 | Common Stock | $1.68 | -$352.80 | 0.04 [ Very Low ] | 465 | $781.20 | 0.09 [Very Low] | Form 4 | - | 2020-04-29 | Dawn Parsell Otto | EVP, Clinical Development | Sell | 210 | Common Stock | $31.98 | $6,715.80 | 0.04 [ Very Low ] | 255 | $8,154.90 | 0.05 [Very Low] | Form 4 | - | 2020-04-29 | Dawn Parsell Otto | EVP, Clinical Development | Buy | 1,744 | Common Stock | $1.68 | -$2,929.92 | 0.35 [ Average ] | 1,999 | $3,358.32 | 0.40 [Very Low] | Form 4 | - | 2020-04-29 | Dawn Parsell Otto | EVP, Clinical Development | Sell | 1,744 | Common Stock | $31.98 | $55,773.12 | 0.35 [ Average ] | 255 | $8,154.90 | 0.05 [Very Low] | Form 4 | - | 2020-04-29 | Dawn Parsell Otto | EVP, Clinical Development | Buy | 523 | Common Stock | $2.39 | -$1,249.97 | 0.10 [ Low ] | 778 | $1,859.42 | 0.16 [Very Low] | Form 4 | - | 2020-04-29 | Dawn Parsell Otto | EVP, Clinical Development | Sell | 523 | Common Stock | $31.98 | $16,725.54 | 0.10 [ Low ] | 255 | $8,154.90 | 0.05 [Very Low] | Form 4 | - | 2020-04-29 | Dawn Parsell Otto | EVP, Clinical Development | Buy | 523 | Common Stock | $7.49 | -$3,917.27 | 0.10 [ Low ] | 778 | $5,827.22 | 0.16 [Very Low] | Form 4 | - | 2020-04-29 | Dawn Parsell Otto | EVP, Clinical Development | Sell | 523 | Common Stock | $31.98 | $16,725.54 | 0.10 [ Low ] | 255 | $8,154.90 | 0.05 [Very Low] | Form 4 | - | 2020-05-01 | Gerrit Klaerner | President and CEO | Sell | 3,050 | Common Stock | $27.68 | $84,424.00 | 0.61 [ Average ] | 556,271 | $15,397,581.28 | 111.36 [Very High] | Form 4 | - | 2020-05-01 | Gerrit Klaerner | President and CEO | Sell | 850 | Common Stock | $28.86 | $24,531.00 | 0.17 [ Low ] | 555,421 | $16,029,450.06 | 111.19 [Very High] | Form 4 | - | 2020-05-01 | Gerrit Klaerner | President and CEO | Sell | 100 | Common Stock | $29.51 | $2,951.00 | 0.02 [ Very Low ] | 555,321 | $16,387,522.71 | 111.17 [Very High] | Form 4 | - | 2020-05-15 | Gerrit Klaerner | President and CEO | Sell | 2,000 | Common Stock | $31.24 | $62,480.00 | 0.40 [ Average ] | 35,323 | $1,103,490.52 | 7.07 [Average] | Form 4 | By Spouse | 2020-05-15 | Gerrit Klaerner | President and CEO | Sell | 2,000 | Common Stock | $31.87 | $63,740.00 | 0.40 [ Average ] | 33,323 | $1,062,004.01 | 6.67 [Average] | Form 4 | By Spouse | 2020-05-05 | Dawn Parsell Otto | EVP, Clinical Development | Buy | 798 | Common Stock | $1.68 | -$1,340.64 | 0.16 [ Low ] | 1,053 | $1,769.04 | 0.21 [Very Low] | Form 4 | - | 2020-05-05 | Dawn Parsell Otto | EVP, Clinical Development | Sell | 798 | Common Stock | $30.05 | $23,979.90 | 0.16 [ Low ] | 255 | $7,662.75 | 0.05 [Very Low] | Form 4 | - | 2020-05-05 | Dawn Parsell Otto | EVP, Clinical Development | Buy | 452 | Common Stock | $2.39 | -$1,080.28 | 0.09 [ Low ] | 707 | $1,689.73 | 0.14 [Very Low] | Form 4 | - | 2020-05-05 | Dawn Parsell Otto | EVP, Clinical Development | Sell | 452 | Common Stock | $30.31 | $13,700.12 | 0.09 [ Low ] | 255 | $7,729.05 | 0.05 [Very Low] | Form 4 | - | 2020-05-11 | Geoffrey M. Parker | Chief Fin. Officer and EVP | Buy | 12,404 | Common Stock | $29.48 | -$365,669.92 | 2.48 [ Very High ] | 72,404 | $2,134,469.92 | 14.49 [Average] | Form 4 | By Geoffrey M. Parker and Jill Gofen Parker Rev. Trust dated 1/27/00 | 2020-05-11 | Geoffrey M. Parker | Chief Fin. Officer and EVP | Buy | 19,854 | Common Stock | $30.36 | -$602,767.44 | 3.97 [ Very High ] | 92,258 | $2,800,952.88 | 18.47 [High] | Form 4 | By Geoffrey M. Parker and Jill Gofen Parker Rev. Trust dated 1/27/00 | 2020-05-12 | Geoffrey M. Parker | Chief Fin. Officer and EVP | Buy | 1,303 | Common Stock | $30.09 | -$39,207.27 | 0.26 [ Low ] | 93,561 | $2,815,250.49 | 18.73 [High] | Form 4 | By Geoffrey M. Parker and Jill Gofen Parker Rev. Trust dated 1/27/00 | 2020-05-12 | Geoffrey M. Parker | Chief Fin. Officer and EVP | Buy | 1,439 | Common Stock | $31.66 | -$45,558.74 | 0.29 [ Average ] | 95,000 | $3,007,700.00 | 19.02 [High] | Form 4 | By Geoffrey M. Parker and Jill Gofen Parker Rev. Trust dated 1/27/00 | 2020-05-08 | Dawn Parsell Otto | EVP, Clinical Development | Buy | 210 | Common Stock | $1.68 | -$352.80 | 0.04 [ Very Low ] | 465 | $781.20 | 0.09 [Very Low] | Form 4 | - | 2020-05-08 | Dawn Parsell Otto | EVP, Clinical Development | Sell | 210 | Common Stock | $31.98 | $6,715.80 | 0.04 [ Very Low ] | 255 | $8,154.90 | 0.05 [Very Low] | Form 4 | - | 2020-05-08 | Dawn Parsell Otto | EVP, Clinical Development | Buy | 830 | Common Stock | $1.68 | -$1,394.40 | 0.17 [ Low ] | 1,085 | $1,822.80 | 0.22 [Very Low] | Form 4 | - | 2020-05-08 | Dawn Parsell Otto | EVP, Clinical Development | Sell | 830 | Common Stock | $31.98 | $26,543.40 | 0.17 [ Low ] | 255 | $8,154.90 | 0.05 [Very Low] | Form 4 | - | 2020-05-08 | Dawn Parsell Otto | EVP, Clinical Development | Buy | 523 | Common Stock | $7.49 | -$3,917.27 | 0.10 [ Low ] | 778 | $5,827.22 | 0.16 [Very Low] | Form 4 | - | 2020-05-08 | Dawn Parsell Otto | EVP, Clinical Development | Sell | 523 | Common Stock | $31.98 | $16,725.54 | 0.10 [ Low ] | 255 | $8,154.90 | 0.05 [Very Low] | Form 4 | - | 2020-05-08 | Dawn Parsell Otto | EVP, Clinical Development | Buy | 1,437 | Common Stock | $2.39 | -$3,434.43 | 0.29 [ Average ] | 1,692 | $4,043.88 | 0.34 [Very Low] | Form 4 | - | 2020-05-08 | Dawn Parsell Otto | EVP, Clinical Development | Sell | 1,437 | Common Stock | $31.98 | $45,955.26 | 0.29 [ Average ] | 255 | $8,154.90 | 0.05 [Very Low] | Form 4 | - | 2020-06-01 | Gerrit Klaerner | President and CEO | Sell | 4,000 | Common Stock | $26.23 | $104,920.00 | - | 551,321 | $14,461,149.83 | - | Form 4 | - | 2020-06-11 | Kathryn E Falberg | - | Buy | 5,670 | Common Stock | $0.00 | $0.00 | - | 42,760 | $0.00 | 8.56 [Average] | Form 4 | - | 2020-06-11 | Veitinger Klaus R Dr | - | Buy | 5,670 | Common Stock | $0.00 | $0.00 | - | 46,985 | $0.00 | 9.41 [Average] | Form 4 | - | 2020-06-11 | Robert J Alpern | - | Buy | 5,670 | Common Stock | $0.00 | $0.00 | - | 143,060 | $0.00 | 28.64 [High] | Form 4 | - | 2020-06-11 | David P Bonita | - | Buy | 5,670 | Common Stock | $0.00 | $0.00 | - | 11,181 | $0.00 | 2.24 [Low] | Form 4 | By David P. Bonita | 2020-06-11 | Sandra I Coufal | - | Buy | 5,670 | Common Stock | $0.00 | $0.00 | - | 222,609 | $0.00 | 44.56 [High] | Form 4 | - | 2020-06-11 | David Hirsch | - | Buy | 5,670 | Common Stock | $0.00 | $0.00 | - | 11,181 | $0.00 | 2.24 [Low] | Form 4 | - | 2020-06-15 | Gerrit Klaerner | President and CEO | Sell | 2,100 | Common Stock | $26.20 | $55,020.00 | - | 29,323 | $768,262.60 | - | Form 4 | By Spouse | 2020-06-15 | Gerrit Klaerner | President and CEO | Sell | 1,900 | Common Stock | $25.71 | $48,849.00 | - | 31,423 | $807,885.33 | - | Form 4 | By Spouse | 2020-07-15 | Gerrit Klaerner | President and CEO | Sell | 4,000 | Common Stock | $26.33 | $105,320.00 | 0.80 [ High ] | 25,323 | $666,754.59 | 5.07 [Average] | Form 4 | By Spouse | 2020-09-10 | Geoffrey M. Parker | Chief Fin. Officer and EVP | Buy | 4,000 | Common Stock | $0.00 | $0.00 | - | 60,837 | $0.00 | 12.16 [Average] | Form 4 | - | 2020-09-10 | Wilhelm Stahl | EVP, Chief Tech Officer | Buy | 4,000 | Common Stock | $0.00 | $0.00 | - | 19,478 | $0.00 | 3.89 [Low] | Form 4 | - | 2020-09-10 | Gerrit Klaerner | President and CEO | Buy | 8,000 | Common Stock | $0.00 | $0.00 | - | 555,993 | $0.00 | 111.09 [Very High] | Form 4 | - | 2020-09-10 | Robert Mckague | EVP, General Counsel | Buy | 4,000 | Common Stock | $0.00 | $0.00 | - | 4,000 | $0.00 | 0.80 [Very Low] | Form 4 | - | 2020-09-10 | Susannah Cantrell | EVP, Chief Comm. Officer | Buy | 4,000 | Common Stock | $0.00 | $0.00 | - | 4,000 | $0.00 | 0.80 [Very Low] | Form 4 | - | 2020-09-10 | Marc Cobo | SVP, Finance & CAO | Buy | 3,000 | Common Stock | $0.00 | $0.00 | - | 3,000 | $0.00 | 0.60 [Very Low] | Form 4 | - | 2020-09-10 | Dawn Parsell Otto | EVP, Clinical Development | Buy | 4,000 | Common Stock | $0.00 | $0.00 | - | 4,637 | $0.00 | 0.93 [Very Low] | Form 4 | - | 2020-12-10 | Geoffrey M. Parker | CFO and EVP | Buy | 15,000 | Common Stock | $6.78 | -$101,700.00 | 2.99 [ Very High ] | 40,000 | $271,200.00 | 7.97 [Average] | Form 4 | By Equity Trust Company, Trustee of the Geoffrey M. Parker Roth IRA | 2020-12-11 | Robert Mckague | EVP, General Counsel | Buy | 10,000 | Common Stock | $7.62 | -$76,200.00 | 1.99 [ High ] | 10,000 | $76,200.00 | 1.99 [Low] | Form 4 | The Robert McKague Living Trust dated July 31, 2019 | 2021-01-11 | Gerrit Klaerner | President and CEO | Sell | 21,489 | Common Stock | $7.49 | $160,952.61 | 4.28 [ Very High ] | 534,504 | $4,003,434.96 | 106.51 [Very High] | Form 4 | - | 2021-01-12 | Gerrit Klaerner | President and CEO | Sell | 9,821 | Common Stock | $7.65 | $75,130.65 | 1.96 [ High ] | 524,683 | $4,013,824.95 | 104.55 [Very High] | Form 4 | - | 2021-01-13 | Gerrit Klaerner | President and CEO | Sell | 15,035 | Common Stock | $7.41 | $111,409.35 | 3.00 [ Very High ] | 509,648 | $3,776,491.68 | 101.55 [Very High] | Form 4 | - | 2021-01-14 | Gerrit Klaerner | President and CEO | Sell | 1,655 | Common Stock | $7.18 | $11,882.90 | 0.33 [ Average ] | 507,993 | $3,647,389.74 | 101.22 [Very High] | Form 4 | - |